Drs Jacob Sands and Jia Luo discuss NUT carcinoma, including diagnostic challenges, emerging treatments, clinical trial options, and the NUT carcinoma registry.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999032. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

NUT Carcinoma: Clinicopathologic Features, Molecular Genetics and Epigenetics https://pubmed.ncbi.nlm.nih.gov/35372003/

The MYC Oncogene — The Grand Orchestrator of Cancer Growth and Immune Evasion https://pubmed.ncbi.nlm.nih.gov/34508258/

SOX2 Is an Oncogenic Driver of Small-Cell Lung Cancer and Promotes the Classic Neuroendocrine Subtype https://pubmed.ncbi.nlm.nih.gov/34593608/

Next-Generation Sequencing in Cancer https://pubmed.ncbi.nlm.nih.gov/34408360/

PET Scanning https://www.ncbi.nlm.nih.gov/books/NBK559089/

Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma https://pubmed.ncbi.nlm.nih.gov/38154515/

International NUT Carcinoma Registry https://nc-registry.org/

Automated Tumor Proportion Score Analysis for PD-L1 (22C3) Expression in Lung Squamous Cell Carcinoma https://pubmed.ncbi.nlm.nih.gov/34354151/

Ewing Sarcoma https://emedicine.medscape.com/article/990378-overview?form=fpf

Improving Lung Cancer Patient Care Through Collaboration, Psychology, and Communication https://www.medscape.com/viewarticle/999028

BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications https://pubmed.ncbi.nlm.nih.gov/37049806/

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma https://clinicaltrials.gov/study/NCT05019716

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors https://clinicaltrials.gov/study/NCT05372640

Development of CDK4/6 Inhibitors: A Five Years Update https://pubmed.ncbi.nlm.nih.gov/33803309/

A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma https://www.clinicaltrials.gov/search?cond=NCT04718675

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors https://clinicaltrials.gov/study/NCT05488548